罗沙替丁联合血浆置换对高脂血症性胰腺炎的影响

Effects of rosatinib combined with plasma exchange on hyperlipidemic pancreatitis

目的:探讨罗沙替丁联合血浆置换对高脂血症性胰腺炎患者的影响。方法:将120例高脂血症胰腺炎患者分为A、B、C3组,A组给予常规治疗、B组在A组基础上给予血浆置换(plasma exchange,PE)治疗,C组在B组基础上给予罗沙替丁治疗,比较3组三酰甘油(triglyceride,TG)、血淀粉酶(amylase,AMY)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、APCHEⅡ评分、应激性溃疡发生率(incidence of stress ulcer,ISU)、ICU住院时间。结果:3组患者治疗前基本资料,TG、AMY、TNF-α、APCHEⅡ评分差异无显著性(P>0.05),治疗后3组指标较治疗前均有所改善(P<0.05),治疗后3组TG、AMY、TNF-α比较,B组C组较A组降低,差异有显著性(P<0.05),B组C组差异无显著性(P>0.05);ISU比较,A组与B组无统计学差异(P>0.05),C组较A组B组降低,差异有显著性(P<0.05);APCHEⅡ评分、ICU住院时间比较,与A组比较,B组、C组减少,差异有显著性(P<0.05),C组较B组减少,差异有显著性(P<0.05)。结论:血浆置换治疗能有效降低TG、AMY、TNF-α,控制APCHEⅡ评分与ICU住院时间,联合罗沙替丁治疗可更好地降低APCHEⅡ评分与ICU住院时间,减少ISU。

OBJECTIVE To evaluate the effects of roxatidine combined with plasma exchange（PE）on hyperlipidemic pancreatitis.METHODS Totally 120 patients with hyperlipidemic pancreatitis were randomly divided into three groups.Patients in group A received conventional treatment.Patients in group B were treated with plasma exchange（PE）and conventional remedy.Patients in group C had roxatidine combined with plasma exchange（PE）in addition to conventional treatment.Triglyceride（TG）,amylase（AMY）,tumor necrosis factor-α（TNF-α）,APCHE Ⅱscores,incidence of stress ulcer（ISU）and ICU length of patient stay（LOPS）were compared.RESULTS There was no significant difference（P〈0.05）in basic information,TG,AMY,TNF-αor APCHE Ⅱ scale before treatment among the three groups.All groups showed improvement（P〈0.05）regarding indexes above after treatment.Compared with group A,group B and group C had significant decreases（P〈0.05）of TG,AMY,TNF-α without significant difference（P〈0.05）.Group C demonstrated a significantly lower ISU（P〈0.05）whereas there was no significant difference between group A and group B.Compared with group A,group B and group C showed significant reduction of APCHE Ⅱ scores and ICU LOPS,with significantly lower results in group C.CONCLUSIONPlasma exchange（PE）can effectively decrease levels of TG,AMY and TNF-α,and reduce ISU,APCHE Ⅱ scores and ICU LOPS whereas it can further lower APCHEⅡ scores,ICU LOPS and ISU when combined with roxatidine.